Akums Drugs and Pharmaceuticals Limited

Material Risks

AI Risk Summary

**Financial Risk Summary: Akums Drugs and Pharmaceuticals Limited** Akums faces critical compliance risk with an estimated financial exposure of ₹7–25 crore in remediation costs, driven by a perfect 10.0/10 compliance score and unknown EPR (Extended Producer Responsibility) applicability—a significant gap for a CDMO handling pharmaceutical waste streams. The company's missing Scope 1 and Scope 2 emissions data suggests incomplete BRSR reporting, creating non-compliance risk under SEBI BRSR Core Expansion mandates, potentially triggering enforcement action or trading restrictions. Water and GHG intensity risks (both 5.0/10) represent moderate operational exposure; with ₹4,118 crore revenue, a 10% energy-efficiency improvement could reduce avoidable carbon costs by ₹10–15 crore annually at India's CCTS benchmark (₹600–900/tonne). Immediate priority: clarify EPR obligations, complete emissions inventory, and formalize ESG governance to mitigate regulatory and market access risks.

Source: Akums Drugs and Pharmaceuticals Limited BRSR Filing, FY -. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.